These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24511019)

  • 21. Does the EQ-5D measure quality of life in schizophrenia?
    Halling Hastrup L; Nordentoft M; Hjorthøj C; Gyrd-Hansen D
    J Ment Health Policy Econ; 2011 Dec; 14(4):187-96. PubMed ID: 22345360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities.
    Blome C; Beikert FC; Rustenbach SJ; Augustin M
    Arch Dermatol Res; 2013 Apr; 305(3):197-204. PubMed ID: 23266843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-reported impact of urinary incontinence--results from treatment seeking women in 14 European countries.
    Monz B; Pons ME; Hampel C; Hunskaar S; Quail D; Samsioe G; Sykes D; Wagg A; Papanicolaou S
    Maturitas; 2005 Nov; 52 Suppl 2():S24-34. PubMed ID: 16297579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality of life, resource consumption and costs of spinal cord stimulation versus conventional medical management in neuropathic pain patients with failed back surgery syndrome (PROCESS trial).
    Manca A; Kumar K; Taylor RS; Jacques L; Eldabe S; Meglio M; Molet J; Thomson S; O'Callaghan J; Eisenberg E; Milbouw G; Buchser E; Fortini G; Richardson J; Taylor RJ; Goeree R; Sculpher MJ
    Eur J Pain; 2008 Nov; 12(8):1047-58. PubMed ID: 18359255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of life utilities for pelvic inflammatory disease health states.
    Smith KJ; Tsevat J; Ness RB; Wiesenfeld HC; Roberts MS
    Sex Transm Dis; 2008 Mar; 35(3):307-11. PubMed ID: 18032995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of educational level on health-related quality of life (HRQL): results from Germany based on the EuroQol 5D (EQ-5D).
    Mielck A; Reitmeir P; Vogelmann M; Leidl R
    Eur J Public Health; 2013 Feb; 23(1):45-9. PubMed ID: 22434205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of health state utilities and quality of life in patients with malignant esophageal Dysphagia.
    Wildi SM; Cox MH; Clark LL; Turner R; Hawes RH; Hoffman BJ; Wallace MB
    Am J Gastroenterol; 2004 Jun; 99(6):1044-9. PubMed ID: 15180723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study.
    Schmitt J; Meurer M; Klon M; Frick KD
    Br J Dermatol; 2008 Feb; 158(2):351-9. PubMed ID: 18070214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The responsiveness of quality of life utilities to change in depression: a comparison of instruments (SF-6D, EQ-5D, and DFD).
    Gerhards SA; Huibers MJ; Theunissen KA; de Graaf LE; Widdershoven GA; Evers SM
    Value Health; 2011; 14(5):732-9. PubMed ID: 21839412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Rationing in German health care with particular consideration of oncology: view points of German stakeholders--a qualitative interview study].
    Lange J; Gönner C; Vollmann J; Rauprich O
    Gesundheitswesen; 2015 Jan; 77(1):8-15. PubMed ID: 24696371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis.
    Kobelt G; Lindgren P; Lindroth Y; Jacobson L; Eberhardt K
    Rheumatology (Oxford); 2005 Sep; 44(9):1169-75. PubMed ID: 15956093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health-related quality of life and utilities in gastric premalignant conditions and malignant lesions: a multicentre study in a high prevalence country.
    Areia M; Alves S; Brito D; Cadime AT; Carvalho R; Saraiva S; Ferreira S; Moleiro J; Pereira AD; Carrasquinho J; Lopes L; Ramada J; Marcos-Pinto R; Pedroto I; Contente L; Eliseu L; Vieira AM; Sampaio M; Sousa HT; Almeida N; Gregório C; Portela F; Sofia C; Braga V; Baginha E; Bana e Costa T; Chagas C; Mendes LL; Magalhães-Costa P; Matos L; Gonçalves FR; Dinis-Ribeiro M
    J Gastrointestin Liver Dis; 2014 Dec; 23(4):371-8. PubMed ID: 25531994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer.
    Lien K; Tam VC; Ko YJ; Mittmann N; Cheung MC; Chan KK
    Curr Oncol; 2015 Dec; 22(6):e443-52. PubMed ID: 26715881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving quality and decreasing cost in gynecologic oncology care. Society of gynecologic oncology recommendations for clinical practice.
    Rimel BJ; Burke WM; Higgins RV; Lee PS; Lutman CV; Parker L
    Gynecol Oncol; 2015 May; 137(2):280-4. PubMed ID: 25735256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing health-related quality of life in gynecologic oncology.
    Nordin AJ; Greimel E;
    Int J Gynecol Cancer; 2010 Nov; 20(8):1301. PubMed ID: 21051967
    [No Abstract]   [Full Text] [Related]  

  • 37. Economic evaluation of Motor Neuron Diseases: a nationwide cross-sectional analysis in Germany.
    Heinrich F; Cordts I; Günther R; Stolte B; Zeller D; Schröter C; Weyen U; Regensburger M; Wolf J; Schneider I; Hermann A; Metelmann M; Kohl Z; Linker RA; Koch JC; Radelfahr F; Schönfelder E; Gardt P; Mohajer-Peseschkian T; Osmanovic A; Klopstock T; Dorst J; Ludolph AC; Schöffski O; Boentert M; Hagenacker T; Deschauer M; Lingor P; Petri S; Schreiber-Katz O
    J Neurol; 2023 Oct; 270(10):4922-4938. PubMed ID: 37356024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The oncology care model and the future of alternative payment models: A gynecologic oncology perspective.
    Aviki EM; Schleicher SM; Boyd L; Liang M; Ko EM; Zanotti K; Moss H
    Gynecol Oncol; 2021 Sep; 162(3):529-531. PubMed ID: 34294415
    [No Abstract]   [Full Text] [Related]  

  • 39. Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth.
    Langenbruch A; Radtke M; Franzke N; Ring J; Foelster-Holst R; Augustin M
    J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):719-26. PubMed ID: 23560545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing economics of treatments for gynecological cancer where clinical effectiveness meets value for money.
    Stoykova B; Dowie R; Kitchener HC
    Int J Gynecol Cancer; 2004; 14(5):762-71. PubMed ID: 15361182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.